Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook ® , LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms .
Patent and License Information: standardbio.com/legal/notices .
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Standard BioToolsLABNGS:LABbiotech investing
LAB
The Conversation (0)
NextSource Materials Announces Updated Feasibility Study Results for Molo Mine Expansion to 150k tpa of SuperFlake Graphite Concentrate

NextSource Materials Announces Updated Feasibility Study Results for Molo Mine Expansion to 150k tpa of SuperFlake Graphite Concentrate

TORONTO, ON / ACCESS Newswire / July 27, 2026 / NextSource Materials Inc. (TSX:NEXT,OTC:NSRCF)(OTCQB:NSRCF) ("NextSource" or "the Company") is pleased to announce the positive results of an updated Technical Feasibility Study ("FS") for a Phase 2 mine expansion of its Molo Graphite Mine Project... Keep Reading...
Lahontan Drills 9.9m Grading 2.40 g/t Au and 50.7 g/t Ag in Santa Fe Mine Stockpile

Lahontan Drills 9.9m Grading 2.40 g/t Au and 50.7 g/t Ag in Santa Fe Mine Stockpile

Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF, OTCQB:LGCXF, FSE:Y2F) (the "Company" or "Lahontan") is pleased to announce the first drill results from its 2026 Sonic core drilling program at the Santa Fe Mine Project. The Sonic drilling campaign is evaluating historic heap leach pads and stockpiles to... Keep Reading...
Lahontan Drills 31m Grading 0.90 g/t Au Oxide at Calvada Central

Lahontan Drills 31m Grading 0.90 g/t Au Oxide at Calvada Central

Lahontan Gold Corp. (TSXV:LG,OTC:LGCXF, OTCQB:LGCXF, FSE:Y2F) (the "Company" or "Lahontan") is pleased to announce additional drill results from its 2026 drilling program at the Santa Fe Mine Project. The drill results reported herein include 188 metres of diamond drilling at Calvada Central... Keep Reading...
New Found Gold Continues to Deliver High-Grade Gold at Queensway

New Found Gold Continues to Deliver High-Grade Gold at Queensway

23.7 g/t Au over 15.88 m from Lotto Channels43.5 g/t Au over 4.75 m from Lotto Underground Infill Drilling New Found Gold Corp. (TSXV: NFG) (NYSE American: NFGC) ("New Found Gold" or the "Company") is pleased to announce channel sample and infill drill results of Phase 2 open pit and underground... Keep Reading...
Brixton Metals Drills 5,015 g/t Silver over 20m in a New Brownfields Discovery Area at Its Langis Project

Brixton Metals Drills 5,015 g/t Silver over 20m in a New Brownfields Discovery Area at Its Langis Project

Included in hole 377 are several ultra-high-grade sub-intervals: 14.00m of 7,150 g/t silver, 1.15m of 74,137 g/t silver and0.65m of 89,125 g/t silver Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to report the discovery of ultra-high-grade silver... Keep Reading...
Person in blue scrubs interacts with a digital interface featuring graphs and medical icons.

Biotech and Pharma Market Trends: Q2 2026 Review and Forecast

Biotech is starting to edge back into focus as investors reassess the durability of the artificial intelligence (AI) trade and look for sectors where AI is producing tangible operational gains. “There are concerns that we’re in an AI bubble, and I think money is starting to go from companies... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks in 2026

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of July 7, the index stood at 6,856.74, up over 20 percent year-to-date. The rise shows that investors are... Keep Reading...
Lexaria Updates Business Development

Lexaria Updates Business Development

(TheNewswire) Kelowna, British Columbia July 6, 2026 TheNewswire Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at... Keep Reading...
Lexaria Updates Business Development

Lexaria Updates Business Development

KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO... Keep Reading...
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Potentially Valuable Novel Compositions Being InvestigatedLexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following... Keep Reading...

Latest News

More News

Interactive Chart

Latest Press Releases

Jaguar Uranium Launches U.S. Government Strategy with Manifest Industries and Adds General Charles Flynn as Advisor

Tinka Provides Results of Silvia NW Geophysical Survey and Outlines Copper Targets

Quarterly Activities/Appendix 5B Cash Flow Report

Trading Halt

Related News

energy investing

Jaguar Uranium Launches U.S. Government Strategy with Manifest Industries and Adds General Charles Flynn as Advisor

precious metals investing

Tinka Provides Results of Silvia NW Geophysical Survey and Outlines Copper Targets

gold investing

Quarterly Activities/Appendix 5B Cash Flow Report

oil and gas investing

Trading Halt

uranium investing

Quarterly Activities/Appendix 5B Cash Flow Report

gold investing

Byron King: Gold, Oil, Uranium — My Outlook and Stocks I Like

nickel investing

Bahia Metals Technical Review Reinforces the Potential of the Mangueiros Main Project